NAT2 and tuberculosis: The absence of CYP2E1 and NAT2 genes may suggest that TB patients in this study have limited ability to metabolize INH, thus leading to sustained elevated plasma levels of the drug, which may increase the risk of experiencing adverse drug reactions.